Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: " A randomized, controlled trial of initial anti-retroviral "
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: A randomized, controlled trial of initial anti-retroviral | AIDS Research and Therapy BioMed Central Research A randomized controlled trial of initial anti-retroviral therapy with abacavir lamivudine zidovudine twice-daily compared to atazanavir once-daily with lamivudine zidovudine twice-daily in HIV-infected patients over 48 weeks ESS100327 the ACTION Study Princy N Kumar 41 Patricia Salvato42 Anthony LaMarca43 Edwin DeJesus44 Parul Patel45 Daniel McClernon45 Allison Florance45 and Mark S Shaefer45 Open Access Address Georgetown University Medical Center Washington DC USA diversified Medical Practice Houston TX USA 3Therafirst Medical Centers Inc Ft. Lauderdale FL USA 4Orlando Immunology Center Orlando FL USA and 5Previous address GlaxoSmithKline Research Triangle Park NC USA Email Princy N Kumar - kumarp@gunet.georgetown.edu Patricia Salvato - psalv36147@aol.com Anthony LaMarca - tony@therafirst.com Edwin DeJesus - edejesus@oicorlando.com Parul Patel - parul.x.patel@gsk.com Daniel McClernon - mcclernonllc@gmail.com Allison Florance - allison.m.florance@gsk.com Mark S Shaefer - mark.s.shaefer@gsk.com Corresponding author tEqual contributors Published 9 April 2009 Received 12 November 2008 AIDS Research and Therapy 2009 6 3 doi 10.1186 1742-6405-6-3 Accepted 9 April 2009 This article is available from http www.aidsrestherapy.cOm content 6 1 3 2009 Kumar et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor or protease inhibitor may not be suitable for a subset of antiretroviral-naive patients such as those with certain co-morbidities women of child-bearing potential and intolerability to components of standard first line therapy. This study was conducted to determine if .